SuperworthEmergent BioSolutions profit margin EBS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −23.0%
- Operating margin, 12 months
- −8.6%
- Net margin on a year earlier
- −39.3 pts
- Peer median
- 11.6%
Over the twelve months to Jun 30, 2026, Emergent BioSolutions kept −23.0% of its revenue as net profit, with an operating margin of −8.6% and a gross margin of 55.9%.
Five years earlier its net margin was 16.9%.
The median for 10 large drugmakers of a similar size is 11.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 7.1% | 13.5% | 56.1% |
| FY2024 | −18.3% | −10.4% | n/a |
| FY2023 | −72.5% | −69.2% | 32.8% |
| FY2022 | −18.9% | −15.2% | 18.9% |
| FY2021 | 12.4% | 19.2% | 58.4% |
| FY2020 | 19.6% | 27.9% | 63.8% |
| FY2019 | 4.9% | 10.3% | 60.8% |
| FY2018 | 8.0% | 11.5% | 58.8% |
| FY2017 | 14.7% | 22.2% | 65.1% |
| FY2016 | 10.6% | 21.6% | 73.1% |
| FY2015 | 12.8% | 21.7% | 80.8% |
| FY2014 | 8.2% | 12.9% | 73.7% |
| FY2013 | 10.0% | 13.7% | 80.1% |
| FY2012 | 8.3% | 10.6% | 83.7% |
| FY2011 | 8.4% | 11.7% | 84.6% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −23.0% | −39.3 pts | −8.6% | |
| Q1 FY26 | −1.3% | +12.4 pts | 9.0% | |
| Q4 FY25 | 7.1% | +25.3 pts | 13.5% | |
| Q3 FY25 | 9.6% | +28.2 pts | 15.0% | |
| Q2 FY25 | 16.4% | +69.6 pts | 12.5% | |
| Q1 FY25 | −13.6% | +34.1 pts | −10.2% | |
| Q4 FY24 | −18.3% | +54.2 pts | −10.4% | |
| Q3 FY24 | −18.6% | +52.0 pts | −12.7% | |
| Q2 FY24 | −53.3% | +2.9 pts | −40.8% | |
| Q1 FY24 | −47.7% | −7.4 pts | −45.5% | |
| Q4 FY23 | −72.5% | −53.5 pts | −69.2% | |
| Q3 FY23 | −70.5% | −73.7 pts | −66.9% |
Against its peers
Companies in Drug Manufacturers - General nearest Emergent BioSolutions' size, closest first, today.
| Company | Profit margin |
|---|---|
| EBSEmergent BioSolutions | −23.0% |
| NATRNatures Sunshine Products | 3.7% |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| COLLCollegium Pharmaceutical | 5.9% |
| ABUSArbutus Biopharma | 84.2% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| OMEROmeros | n/m |
| Peer median | 11.6% |
Where Emergent BioSolutions ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Emergent BioSolutions
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.